A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70064 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Jonas Hannestad und 16 weiteren Autor:innen. Beteiligte Einrichtung: Tranquis Therapeutics, Inc., Palo Alto, California, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Healthy Volunteers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
TQS‐168, a first‐in‐class small‐molecule inducer of peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha gene expression, is in development for the treatment of amyotrophic lateral sclerosis. A single‐ascending‐dose (SAD) and multiple‐ascending‐dose (MAD) study of TQS‐168 was carried out in healthy male subjects to investigate safety, tolerability, pharmacokinetics (PK), food effect, and preliminary pharmacodynamic effects (PD). Since solubility enhancement could be beneficial, assessment of three formulations was incorporated into the study using an integrated rapid manufacturing and clinical testing approach. Dosing in the SAD part was initiated with a crystalline methylcellulose (MC) suspension, and then spray‐dried dispersion (SDD) and hot‐melt extrusion (HME) suspensions were evaluated. The HME and SDD formulations showed two and fourfold higher exposure than the MC suspension, respectively, and the SDD formulation was selected for progression to subsequent SAD and MAD cohorts, in which there was further investigation of the food effect on exposure in addition to assessments of safety, tolerability, PK, and PD. C max and AUC plasma exposures of TQS‐168 were supra‐proportional at higher doses, irrespective of formulation. Median T max for TQS‐168 occurred between 0.5 and 4.0 h post‐dose and occurred later with higher doses. Geometric mean half‐lives ( T 1/2 ) for TQS‐168 were independent of formulation and food, ranging from 3.2 to 10.5 h following single doses and 4.1 to 7.3 h following multiple doses. Food blunted TQS‐168 C max but had minimal impact on AUC. TQS‐168 was considered to be safe and generally well tolerated following single and multiple oral doses. The SDD formulation was selected for future patient studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tranquis Therapeutics, Inc., Palo Alto, California, USA.
- Quotient Sciences Ltd, Nottingham, UK.
ORCID-Profile: Jonas Hannestad, Steven Smith, Juliana Brunello, Vanessa Zann, Enchi Liu
Zitieren
APA
Hannestad, J., Smith, S., Lam, A., Hurt, J., Harada, N., Kim, R., Das, A., Brunello, J., Whitaker, G., Chalmers, D., Senjoti, F., Lin, W., Coghill, J., Bansal, Y., Sidhu, S., Zann, V., & Liu, E. (2024). A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect. Clinical and Translational Science. https://doi.org/10.1111/cts.70064
Vancouver
Hannestad J, Smith S, Lam A, Hurt J, Harada N, Kim R, et al. A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect. Clinical and Translational Science. 2024. doi:10.1111/cts.70064
BibTeX
@article{Hannestad2024,
author = {Hannestad, Jonas and Smith, Steven and Lam, Andrew and Hurt, Janet and Harada, Nicole and Kim, Richard and Das, Abhirup and Brunello, Juliana and Whitaker, Gareth and Chalmers, David and Senjoti, Faria and Lin, Wu and Coghill, James and Bansal, Yogesh and Sidhu, Sharan and Zann, Vanessa and Liu, Enchi},
title = {A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70064}
}
EUVIMED